JPS58174330A - ガン壊死因子の安定化法 - Google Patents

ガン壊死因子の安定化法

Info

Publication number
JPS58174330A
JPS58174330A JP57056690A JP5669082A JPS58174330A JP S58174330 A JPS58174330 A JP S58174330A JP 57056690 A JP57056690 A JP 57056690A JP 5669082 A JP5669082 A JP 5669082A JP S58174330 A JPS58174330 A JP S58174330A
Authority
JP
Japan
Prior art keywords
tnf
solution
activity
albumin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57056690A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0375529B2 (OSRAM
Inventor
Hajime Sakamoto
肇 阪本
Takao Kiyota
清田　隆夫
Hiroshi Hayashi
林　紘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Asahi Chemical Industry Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Asahi Chemical Industry Co Ltd
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd, Asahi Chemical Industry Co Ltd, Asahi Kasei Kogyo KK filed Critical Dainippon Pharmaceutical Co Ltd
Priority to JP57056690A priority Critical patent/JPS58174330A/ja
Priority to US06/477,866 priority patent/US4447355A/en
Priority to HU83981A priority patent/HU189251B/hu
Priority to DE8383301740T priority patent/DE3373628D1/de
Priority to AT83301740T priority patent/ATE29666T1/de
Priority to EP83301740A priority patent/EP0091258B2/en
Priority to CA000424749A priority patent/CA1187412A/en
Priority to FR8305540A priority patent/FR2530472B1/fr
Priority to IT67372/83A priority patent/IT1162845B/it
Priority to BE0/210494A priority patent/BE896383A/fr
Priority to KR1019830001415A priority patent/KR860000842B1/ko
Priority to ES521266A priority patent/ES521266A0/es
Priority to CH1885/83A priority patent/CH656534A5/fr
Publication of JPS58174330A publication Critical patent/JPS58174330A/ja
Publication of JPH0375529B2 publication Critical patent/JPH0375529B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP57056690A 1982-04-07 1982-04-07 ガン壊死因子の安定化法 Granted JPS58174330A (ja)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP57056690A JPS58174330A (ja) 1982-04-07 1982-04-07 ガン壊死因子の安定化法
US06/477,866 US4447355A (en) 1982-04-07 1983-03-23 Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
HU83981A HU189251B (en) 1982-04-07 1983-03-23 Process for stabilizing tumor necrosis factor
DE8383301740T DE3373628D1 (en) 1982-04-07 1983-03-28 Method for stabilizing tumor necrosis factor and a stable aqueous solution or powder containing said factor
AT83301740T ATE29666T1 (de) 1982-04-07 1983-03-28 Verfahren zur stabilisierung eines die nekrose von tumoren induzierenden faktors und stabile waesserige loesung oder pulver mit diesem faktor.
EP83301740A EP0091258B2 (en) 1982-04-07 1983-03-28 Method for stabilizing tumor necrosis factor and a stable aqueous solution or powder containing said factor
CA000424749A CA1187412A (en) 1982-04-07 1983-03-29 Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
FR8305540A FR2530472B1 (fr) 1982-04-07 1983-04-05 Procede pour stabiliser un facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur
IT67372/83A IT1162845B (it) 1982-04-07 1983-04-05 Procedimento per stabilizzare un fattore avente effetto necrotizzante sui tumori e soluzione acquosa stabile o polvere che lo contiene
BE0/210494A BE896383A (fr) 1982-04-07 1983-04-06 Procede pour stabiliser un facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur
KR1019830001415A KR860000842B1 (ko) 1982-04-07 1983-04-06 종양 괴사 인자의 안정화 방법
ES521266A ES521266A0 (es) 1982-04-07 1983-04-06 Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores.
CH1885/83A CH656534A5 (fr) 1982-04-07 1983-04-07 Procede pour stabiliser un facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57056690A JPS58174330A (ja) 1982-04-07 1982-04-07 ガン壊死因子の安定化法

Publications (2)

Publication Number Publication Date
JPS58174330A true JPS58174330A (ja) 1983-10-13
JPH0375529B2 JPH0375529B2 (OSRAM) 1991-12-02

Family

ID=13034438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57056690A Granted JPS58174330A (ja) 1982-04-07 1982-04-07 ガン壊死因子の安定化法

Country Status (2)

Country Link
JP (1) JPS58174330A (OSRAM)
BE (1) BE896383A (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126217A (ja) * 1983-12-14 1985-07-05 Sumitomo Chem Co Ltd 長期徐放性製剤
JPS63152326A (ja) * 1986-07-18 1988-06-24 Chugai Pharmaceut Co Ltd 安定な顆粒球コロニ−刺激因子含有製剤
WO1989006532A1 (fr) * 1988-01-13 1989-07-27 Dainippon Pharmaceutical Co., Ltd. Preparation contenant des liposomes et ne suintant pas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55108821A (en) * 1979-02-14 1980-08-21 Kanebo Ltd Preparation of antitumor agent
JPS5716823A (en) * 1980-07-03 1982-01-28 Green Cross Corp:The Live mumps vaccine pharmaceutical and stabilizing method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55108821A (en) * 1979-02-14 1980-08-21 Kanebo Ltd Preparation of antitumor agent
JPS5716823A (en) * 1980-07-03 1982-01-28 Green Cross Corp:The Live mumps vaccine pharmaceutical and stabilizing method

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126217A (ja) * 1983-12-14 1985-07-05 Sumitomo Chem Co Ltd 長期徐放性製剤
JPS63152326A (ja) * 1986-07-18 1988-06-24 Chugai Pharmaceut Co Ltd 安定な顆粒球コロニ−刺激因子含有製剤
WO1989006532A1 (fr) * 1988-01-13 1989-07-27 Dainippon Pharmaceutical Co., Ltd. Preparation contenant des liposomes et ne suintant pas

Also Published As

Publication number Publication date
BE896383A (fr) 1983-08-01
JPH0375529B2 (OSRAM) 1991-12-02

Similar Documents

Publication Publication Date Title
KR860000842B1 (ko) 종양 괴사 인자의 안정화 방법
RU2108341C1 (ru) Способ получения кристаллов гр или производных гр, кристаллы человеческих гр или производных человеческих гр и фармацевтический препарат
JPS60258125A (ja) 蛋白性生理活性物質を含有する水溶性乾燥物
Brennan et al. The growth of Candida albicans in nutritive solutions given parenterally
Sorensen et al. An effective therapeutic regimen for the hemopoietic phase of the acute radiation syndrome in dogs
JPH03505334A (ja) 凍結乾燥されたペプチド製剤
JPH0725688B2 (ja) Ｃｓｆ徐放性製剤
JPS58174330A (ja) ガン壊死因子の安定化法
US5780599A (en) Growth hormone crystals and a process for production of growth hormone crystals
Penttila et al. Studies on the modification of the cellular response to injury: II. Electron microscopic studies on the protective effect of acidosis on anoxic injury of ehrlich ascites tumor cells
JPS5959625A (ja) ガン壊死因子を安定化する方法
CN1012375B (zh) 鸡精液稀释液
Roitiberg et al. Observations on chimpanzees after whole-body radiation and homologous bone marrow treatment
JPH0375530B2 (OSRAM)
Ribble Increase of plasma lysozyme activity following injections of typhoid vaccine.
Nordstoga et al. Porcine Salmonellosis: II. Production of the Generalized Shwartzman Reaction by Intravenous Injections of Disintegrated Cells of Salmonella Cholerae-Suis
RU2140283C1 (ru) Фармацевтический препарат на основе интерлейкина-2 (варианты)
Greenfield et al. Studies on the anemia of tumor-bearing animals. II. The mechanism of erythrocyte destruction
Baker et al. Mono-substituted vit. B12 amides. I. A microbiological study.
McDonald et al. Stimulation of megakaryocytic spleen colonies in mice by thrombopoietin
JPS5939829A (ja) ガン壊死因子安定化法
US6894023B1 (en) Growth hormone crystals and a process for production of these GH-crystals
Powell et al. On the efficacy of Merthiolate as a biological preservative after ten years' use
Domaradskii et al. EFFECT OF PASTEURELLA PESTIS TOXIN ON THE HISTAMINOPEXIC EFFECT OF THE BLOOD OF ALBINO RATS AND GUINEA PIGS
Anderson The response of young pigs to Escherichia coli endotoxin.